Integrated Diagnostics (IDHC) Share Price, News & Analysis

Company Overview

IDH is a leading diagnostics services provider in the Middle East and Africa offering a broad range of pathology and radiology tests to patients in Egypt, Jordan, Sudan and Nigeria. The Group’s core brands include Al Borg, Al Borg Scan and Al Mokhtabar in Egypt, as well as Biolab (Jordan), Ultralab and Al Mokhtabar Sudan (both in Sudan) and Echo-Lab (Nigeria). A long track record for quality and safety has earned the Company a trusted reputation, as well as internationally recognised accreditations for its portfolio of over 2,000 diagnostics tests. From its base of 552 branches as of 31 December 2022, IDH served over 8.7 million patients and performs more than 32.7 million tests in 2022. IDH will continue to add laboratories through a Hub, Spoke and Spike business model that provides a scalable platform for efficient expansion. Beyond organic growth, the Group’s expansion plans include acquisitions in new Middle Eastern, African, and East Asian markets where its model is well-suited to capitalise on similar healthcare and consumer trends and capture a significant share of fragmented markets. IDH has been a Jersey-registered entity with a Standard Listing on the Main Market of the London Stock Exchange (ticker: IDHC) since May 2015 with a secondary listing on the EGX since May 2021 (ticker: IDHC.CA).

Key Stats

• Today's Range: 0.45 to 0.45
• 50-Day Range: 0.37 to 0.53
• 52-Week Range: 0.28 to 0.54
• Volume: 2 shs
• Average Volume: 369,935 shs
• Market Capitalization: £2.62 million
• P/E Ratio: 15.00
• Dividend Yield: 2,222.22%
• Price Target: N/A
• Consensus Rating: N/A

IDHC Stock Analysis - Frequently Asked Questions

How have IDHC shares performed this year?

Integrated Diagnostics' stock was trading at GBX 0.36 at the beginning of the year. Since then, IDHC shares have increased by 26.8% and is now trading at GBX 0.45.
View the best growth stocks for 2024 here.

How do I buy shares of Integrated Diagnostics?

Shares of IDHC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of Integrated Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Integrated Diagnostics investors own include Georgia Healthcare Group PLC (GHG.L) (GHG), VEON (VEON), Pao Tmk (TMKXY) and M.P. Evans Group (MPE).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Diagnostics & Research
• Sub-Industry: N/A
• Current Symbol: LON:IDHC
• CUSIP: N/A
• CIK: N/A
• Web: www.idhcorp.com
• Phone: +44-1534-847000
• Fax: N/A
• Employees: 6,692
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX 0.03
• Trailing P/E Ratio: 15.00
• Forward P/E Ratio: 0.32
• P/E Growth: 7.65
• Net Income: £817.28 million
• Net Margins: 17.21%
• Pretax Margin: N/A
• Return on Equity: 23.03%
• Return on Assets: 9.69%

Debt

• Debt-to-Equity Ratio: 35.86
• Current Ratio: 1.59
• Quick Ratio: 0.75

Sales & Book Value

• Annual Sales: £4.75 billion
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: GBX 464 per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 581,330,000
• Free Float: N/A
• Market Cap: £2.62 million
• Optionable: Not Optionable
• Beta: 0.59